Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: A meta-analysis

Auraptene (AUR) and umbelliprenin (UMB) are naturally occurring prenylated coumarins that have demonstrated promising anticancer effects across various human cancer cell lines. This meta-analysis aimed to systematically assess, compare, and quantify the anticancer efficacy of AUR and UMB by synthesizing evidence from in vitro studies. A comprehensive literature search identified 27 eligible studies investigating AUR or UMB against cancer cells. Mixed-effects models revealed significant negative associations between coumarin dose and viability for AUR (est. = − 2.27) and UMB (est. = − 3.990), underscoring their dose-dependent cytotoxicity. Meta-regression indicated slightly higher potency for UMB over AUR, potentially due to increased lipophilicity imparted by additional isoprenyl units. Machine learning approaches identified coumarin dose and cancer type as the most influential determinants of toxicity, while treatment duration and the specific coumarin displayed weaker effects. Moderat..., , , > Introduced by Shakiba et al. in [Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: a meta-analysis](https://www.nature.com/articles/s41598-024-62747-z)

**This dataset contains quantitative data on the anticancer effects of the natural coumarins Auraptene (AUR) and Umbelliprenin (UMB) across 27 studies. The data were collected from published literature reporting the impacts of AUR and UMB treatment on the viability of diverse human cancer cell lines.**

## Data Contents

The dataset is provided as a single .xlsx file containing three sheets: one for AUR, one for UMB, and one combined with the following columns:

* `author`: First author's last name from publication
* `year`: Publication year
* `cancerType`: Cancer type examined
* `cellLine`: Specific cell line utilized
* `time`: Treatment duration (in hours)
* `coumarin`: Coumarin used (AUR or UMB)
* `coumarinDose`: Dosage of coumarin (in μM)
* `viability`: Mean viability (%) in treatment group
* `viabil...